Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China

PURPOSE: To evaluate the cost utility of camrelizumab plus standard chemotherapy versus standard chemotherapy alone as a first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) from the perspective of the Chinese health care system and to provide a reference for health decis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ting, Xie, Ruixiang, Zhao, Qiuling, Cai, Hongfu, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353739/
https://www.ncbi.nlm.nih.gov/pubmed/35936702
http://dx.doi.org/10.3389/fonc.2022.746526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353739/
https://www.ncbi.nlm.nih.gov/pubmed/35936702
http://dx.doi.org/10.3389/fonc.2022.746526

Ejemplares similares